A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Vertex Pharmaceuticals Incorporated
Related studies linked through entity extraction aliases.
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
- Status
- TERMINATED
- Phase
- PHASE2
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
- Status
- TERMINATED
- Phase
- PHASE4
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
- Status
- TERMINATED
- Phase
- PHASE3
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
- Status
- TERMINATED
- Phase
- PHASE3
VX-770 Expanded Access Program
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
- Status
- COMPLETED
- Phase
- PHASE2
VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
- Status
- COMPLETED
- Phase
- PHASE1
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
- Status
- COMPLETED
- Phase
- PHASE3
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Study of VX-770 on Desipramine
- Status
- COMPLETED
- Phase
- PHASE1
Study of VX-985 in Subjects With Chronic Hepatitis C
- Status
- COMPLETED
- Phase
- PHASE1
Rollover Study of VX-770 in Cystic Fibrosis Subjects
- Status
- COMPLETED
- Phase
- PHASE3
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
- Status
- TERMINATED
- Phase
- PHASE2